Ohio is currently home to 3199 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
NCT05786040
Recruiting
This phase II trial tests how well tafasitamab and rituximab work for front-line treatment of patients with post-transplant lymphoproliferative disorder. Post-transplant lymphoproliferative disorder (PTLD) is the name for types of lymphoma that sometimes develop in people who have had a transplant. It can affect people who are taking medicines to suppress their immune system. Tafasitamab injection is in a class of medications called monoclonal antibodies. It works by helping the body to slow or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder
Register for Updates
A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
NCT05568459
Recruiting
This study is focused on males who have Hemophilia B and who need regular preventive treatment with factor IX protein (FIX) replacement therapy to prevent and also to control their bleeding events. The aim of the study is to gather at least 6 months of information on bleeding events for each individual participant while they continue to use their usual FIX replacement therapy. There is no experimental treatment being tested in this study. The study is informational, and part of a larger program... Read More
Gender:
MALE
Ages:
16 years and above
Trial Updated:
02/19/2025
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Hemophilia B
Register for Updates
4D-710 in Adult Patients With Cystic Fibrosis
NCT05248230
Recruiting
This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Cystic Fibrosis Lung
Register for Updates
Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation
NCT04088071
Recruiting
The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Register for Updates
To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome
NCT06840496
Recruiting
Primary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome Key Secondary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and women with Rett syndrome
Gender:
FEMALE
Ages:
Between 5 years and 20 years
Trial Updated:
02/18/2025
Locations: Biomed Testing Facility #BIO-15-45229, Cincinnati, Ohio
Conditions: Rett Syndrome
Register for Updates
Evaluation of Wear Experience with a Weekly Replacement Soft Contact Lens in Neophyte Lens Wearers with Astigmatism
NCT06751225
Recruiting
This open-label study is of adults with astigmatism who have never worn contact lenses. Subjects will be fit into a one week planned-replacement contact lenses and will wear lenses for approximately 3 weeks. Subjects will return for vision and lens fit assessments and will complete surveys about their wear experience.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
02/18/2025
Locations: The Ohio State University College of Optometry, Columbus, Ohio
Conditions: Astigmatism Bilateral
Register for Updates
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
NCT06605599
Recruiting
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how safe and effective ABBV-932 is in treating participants with bipolar I or II disorder. ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Study doctors put participants in 1 of 4 groups, called treatment arms. There is a 1 in 4 chance that a participant will... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/18/2025
Locations: Quest Therapeutics of Avon Lake /ID# 267558, Avon Lake, Ohio
Conditions: Bipolar I Disorder, Bipolar II Disorder
Register for Updates
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
NCT06604442
Recruiting
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men with Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Prostate Cancer
Register for Updates
Infant Formula in Infants and Children With Cow's Milk Allergy
NCT06456541
Recruiting
This is a multi-center, randomized, double-blinded, placebo-controlled food challenge to be conducted in infants and children with confirmed IgE-mediated cow's milk allergy (CMA), followed by a 7-day open feeding of the experimental formula.
Gender:
ALL
Ages:
Between 3 months and 12 years
Trial Updated:
02/18/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Cow's Milk Allergy
Register for Updates
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376
Recruiting
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Research Site, Columbus, Ohio
Conditions: Immunoglobulin A Nephropathy, IgAN
Register for Updates
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients with Peritoneal Metastases from Colorectal Cancer
NCT06269978
Recruiting
This phase I trial tests the safety, side effects, and best dose of intraperitoneal oxaliplatin and fluorouracil in treating patients with colorectal cancer that has spread to the peritoneal cavity (peritoneal metastasis). Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill cancer cells. Fluorouracil stops cells from making DNA and it may kill cancer cells. Both oxaliplatin and fluorouracil are approved by the Food and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Colorectal Cancer AJCC v8
Register for Updates
MCG As a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)
NCT06212466
Recruiting
A prospective, multicenter, observational, single-arm trial to validate CardioFlux MCG's ability to diagnose myocardial ischemia caused by coronary microvascular dysfunction in patients with suspected ischemia and confirmed no obstructive coronary artery disease (suspected INOCA) by using diagnostic measures of coronary flow reserve (CFR) via invasive angiography as a reference standard for diagnosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: The Christ Hospital, Cincinnati, Ohio
Conditions: Ischemic Heart Disease, Coronary Microvascular Disease, Angina, Myocardial Ischemia
Register for Updates